ATE549023T1 - Formulierungen mit jorumycin-, renieramycin-, safracin- oder saframycin-verwandten verbindungen und einen disaccharide zur behandlung von proliferativen erkrankungen - Google Patents

Formulierungen mit jorumycin-, renieramycin-, safracin- oder saframycin-verwandten verbindungen und einen disaccharide zur behandlung von proliferativen erkrankungen

Info

Publication number: ATE549023T1
Authority: AT; Austria
Prior art keywords: jorumycin; renieramycin; safracin; saframycin; related compounds
Prior art date: 2005-10-31

Application number

AT06795019T

Other languages

English (en)

Inventor

Salve Pilar Calvo

Barreira Maria Tobio

Original Assignee

Pharma Mar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-31

Filing date

2006-10-30

Publication date

2012-03-15

2006-10-30 Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE549023T1 publication Critical patent/ATE549023T1/de

Links

239000000203 mixture Substances 0.000 title abstract 4
229930183496 Safracin Natural products 0.000 title abstract 2
QCUVHQFXYHRYHX-PIHYCAAOSA-N chembl539920 Chemical compound C([C@H](N1C)[C@@H]2O)C(C(C(C)=C(OC)C3=O)=O)=C3[C@@H]1[C@H](C1)N2[C@@H](COC(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O QCUVHQFXYHRYHX-PIHYCAAOSA-N 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title abstract 2
201000010099 disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
QCUVHQFXYHRYHX-UHFFFAOYSA-N jorumycin Natural products OC1C(N2C)CC(C(C(C)=C(OC)C3=O)=O)=C3C2C(C2)N1C(COC(C)=O)C1=C2C(=O)C(C)=C(OC)C1=O QCUVHQFXYHRYHX-UHFFFAOYSA-N 0.000 title abstract 2
230000002062 proliferating effect Effects 0.000 title abstract 2
229930188681 renieramycin Natural products 0.000 title abstract 2
150000002016 disaccharides Chemical class 0.000 title 1
238000009472 formulation Methods 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
229930190585 Saframycin Natural products 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT06795019T 2005-10-31 2006-10-30 Formulierungen mit jorumycin-, renieramycin-, safracin- oder saframycin-verwandten verbindungen und einen disaccharide zur behandlung von proliferativen erkrankungen ATE549023T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0522082.7A GB0522082D0 (en)	2005-10-31	2005-10-31	Formulations
PCT/GB2006/050362 WO2007052076A2 (en)	2005-10-31	2006-10-30	Formulations comprising jorumycin-, reni eramycin-, safracin- or saframycin-related compounds for treating proliferative diseases

Publications (1)

Publication Number	Publication Date
ATE549023T1 true ATE549023T1 (de)	2012-03-15

Family

ID=35515969

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06795019T ATE549023T1 (de)	2005-10-31	2006-10-30	Formulierungen mit jorumycin-, renieramycin-, safracin- oder saframycin-verwandten verbindungen und einen disaccharide zur behandlung von proliferativen erkrankungen

Country Status (23)

Country	Link
US (1)	US9192568B2 (de)
EP (1)	EP1968592B1 (de)
JP (1)	JP5197373B2 (de)
KR (1)	KR101434230B1 (de)
CN (1)	CN101300011B (de)
AT (1)	ATE549023T1 (de)
AU (1)	AU2006310260C1 (de)
CA (1)	CA2625096C (de)
DK (1)	DK1968592T3 (de)
ES (1)	ES2383967T3 (de)
GB (1)	GB0522082D0 (de)
HR (1)	HRP20120478T1 (de)
IL (1)	IL190774A (de)
NO (1)	NO341057B1 (de)
NZ (1)	NZ567291A (de)
PL (1)	PL1968592T3 (de)
PT (1)	PT1968592E (de)
RS (1)	RS52312B (de)
RU (1)	RU2429845C2 (de)
SI (1)	SI1968592T1 (de)
UA (1)	UA97629C2 (de)
WO (1)	WO2007052076A2 (de)
ZA (1)	ZA200803420B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0117402D0 (en) *	2001-07-17	2001-09-05	Pharma Mar Sa	New antitumoral derivatives of et-743
GB0708691D0 (en) *	2007-05-04	2007-06-13	Pharma Mar Sa	Anticancer treatments a
CA2724206A1 (en) *	2008-05-16	2009-11-19	Pharma Mar S.A.	Multiple myeloma treatments
CA2724325A1 (en) *	2008-05-16	2009-11-19	Pharma Mar, S.A.	Combination therapy with an antitumor alkaloid
WO2011048210A1 (en)	2009-10-22	2011-04-28	Pharma Mar, S.A.	PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
CA3024230C (en)	2011-04-28	2022-10-18	Oncopeptides Ab	Lyophilized preparation of cytotoxic dipeptides
WO2014065751A1 (en)	2012-10-26	2014-05-01	Oncopeptides Ab	Lyophilized preparations of melphalan flufenamide
HRP20231233T1 (hr)	2017-04-27	2024-01-19	Pharma Mar, S.A.	Antitumorski spojevi
WO2019018539A1 (en) *	2017-07-19	2019-01-24	California Institute Of Technology	PROCESSES FOR PREPARING COMPOUNDS CONTAINING BIS-TETRAHYDROISOQUINOLINE
US20240197726A1 (en) *	2021-03-03	2024-06-20	The University Of Tokyo	Novel tetrahydroisoquinoline alkaloid compound containing macrocycle

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5256663A (en) *	1986-06-09	1993-10-26	The Board Of Trustees Of The University Of Illinois	Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) *	1990-11-30	1992-09-22	The Board Of Trustees Of The University Of Illinois	Ecteinascidins 736 and 722
US5089273A (en) *	1986-06-09	1992-02-18	Board Of Trustees Of The University Of Illinois	Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) *	1986-10-21	1988-04-28	Knoll Ag	5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5336669A (en)	1991-12-10	1994-08-09	Erbamont, Inc.	Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) *	1993-12-02	1995-12-26	The Board Of Trustees Of The University Of Illinois	Ecteinascidins
US20040059112A1 (en) *	1994-02-18	2004-03-25	Rinehart Kenneth L.	Ecteinascidins
GB9508195D0 (en) *	1995-04-20	1995-06-07	Univ British Columbia	Novel biologically active compounds and compositions,their use and derivation
DE19605212A1 (de) *	1996-02-13	1997-08-14	Basf Ag	Phosphordotiertes Silberkatalysator-Festbett
US5721362A (en) *	1996-09-18	1998-02-24	President And Fellows Of Harvard College	Process for producing ecteinascidin compounds
US5985876A (en)	1997-04-15	1999-11-16	Univ Illinois	Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
AU7589898A (en)	1997-05-21	1998-12-11	Genentech Inc.	Novel administration of thrombopoietin
CN1157189C (zh)	1998-04-06	2004-07-14	伊利诺伊大学评议会	半合成海鞘素
EP1077698B1 (de)	1998-05-11	2005-03-02	Pharma Mar, S.A.	Ecteinascidinderivate
JP2000081438A (ja)	1998-06-25	2000-03-21	Sekisui Chem Co Ltd	被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) *	1998-09-30	2000-09-26	President And Fellows Of Harvard College	Synthetic analogs of ecteinascidin-743
MY164077A (en) *	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
MY130271A (en) *	1999-05-14	2007-06-29	Pharma Mar Sa	Hemisynthetic method and new compounds
JP5219323B2 (ja)	2000-04-12	2013-06-26	ファルマ・マール・ソシエダード・アノニマ	抗腫瘍性エクチナサイジン誘導体
MXPA02011319A (es) *	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) *	2000-05-15	2008-09-02	Pharma Mar, S.A.	Synthetic process for the manufacture of an ecteinaschidin compound
US20020137663A1 (en) *	2000-08-11	2002-09-26	Forman Barry M.	The anti-neoplastic agent ET-743 inhibits trans activation by SXR
ES2256305T3 (es) *	2000-10-31	2006-07-16	Pharma Mar, S.A.	Formulaciones de kahalalide f.
EP1339713A2 (de) *	2000-11-03	2003-09-03	President And Fellows Of Harvard College	Saframycine, analogen und deren verwendung
EP1365808B1 (de)	2000-11-06	2011-01-19	Pharma Mar, S.A.	Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
IL156580A0 (en)	2001-01-25	2004-01-04	Bristol Myers Squibb Co	A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
WO2002064843A1 (en)	2001-02-09	2002-08-22	The Regents Of The University Of California	Ecteinascidin family compounds: compositions and methods
EE200300429A (et) *	2001-03-06	2003-12-15	Bristol-Myers Squibb Company	Tegafuri, uratsiili, foliinhappe, paklitakseeli ja karboplatiini kasutamine ravimkoostise valmistamiseks kasvaja raviks
US20030027799A1 (en)	2001-03-30	2003-02-06	Shire Biochem Inc.	Methods of treating cancer using a combination of drugs
GB0121285D0 (en)	2001-09-03	2001-10-24	Cancer Res Ventures Ltd	Anti-cancer combinations
BR0213424A (pt)	2001-10-19	2004-12-14	Pharma Mar Sa	Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US20040019027A1 (en) *	2002-04-12	2004-01-29	Barry Forman	Method of treating cerebrotendinous xanthomatosis
GB0218813D0 (en)	2002-08-13	2002-09-18	Pharma Mar Sa	DNA sequences from an endosymbiont and their uses
GB0229793D0 (en)	2002-12-20	2003-01-29	Pharma Mar Sa	The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0312407D0 (en) *	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
US7251892B2 (en) *	2003-07-09	2007-08-07	Temper Corporation	Bearing assembly spacer adjustable system and method for adjusting a spacer
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
DE602004016376D1 (de)	2003-11-13	2008-10-16	Pharma Mar Sau	Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
CA2545054A1 (en) *	2003-11-14	2005-06-02	Pharma Mar, S.A.	Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
WO2005118584A2 (en) *	2004-05-26	2005-12-15	Axys Pharmaceuticals, Inc.	Saframycin analogs as therapeutic agents in the treatment of cancer
MX2007000360A (es) *	2004-07-09	2007-06-12	Pharma Mar Sa	Marcadores moleculares de pronostico.
AU2005288696A1 (en)	2004-09-28	2006-04-06	Pharma Mar S.A., Sociedad Unipersonal	Ecteinascidin compounds as anti -inflammatory agents
DK1827500T3 (da) *	2004-10-26	2009-08-31	Pharma Mar Sa	Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
RS50510B (sr) *	2004-10-29	2010-03-02	Pharma Mar S.A., Sociedad Unipersonal	Formulacije koje sadrže ekteinascidin i disaharid
WO2006066183A2 (en) *	2004-12-16	2006-06-22	Axys Pharmaceuticals, Inc.	Novel saframycin analogs as therapeutic agents
DE602006020335D1 (de) *	2005-11-25	2011-04-07	Pharma Mar Sa	Verwendung von parp-1-hemmern
JP2009536956A (ja) *	2006-05-12	2009-10-22	ファルマ・マール・ソシエダード・アノニマ	抗癌治療法

2005
- 2005-10-31 GB GBGB0522082.7A patent/GB0522082D0/en not_active Ceased
2006
- 2006-10-30 EP EP06795019A patent/EP1968592B1/de active Active
- 2006-10-30 UA UAA200807478A patent/UA97629C2/ru unknown
- 2006-10-30 AU AU2006310260A patent/AU2006310260C1/en not_active Ceased
- 2006-10-30 KR KR1020087010283A patent/KR101434230B1/ko not_active Expired - Fee Related
- 2006-10-30 CN CN2006800404704A patent/CN101300011B/zh not_active Expired - Fee Related
- 2006-10-30 PT PT06795019T patent/PT1968592E/pt unknown
- 2006-10-30 PL PL06795019T patent/PL1968592T3/pl unknown
- 2006-10-30 WO PCT/GB2006/050362 patent/WO2007052076A2/en not_active Ceased
- 2006-10-30 US US12/091,540 patent/US9192568B2/en not_active Expired - Fee Related
- 2006-10-30 DK DK06795019.6T patent/DK1968592T3/da active
- 2006-10-30 JP JP2008537207A patent/JP5197373B2/ja not_active Expired - Fee Related
- 2006-10-30 CA CA2625096A patent/CA2625096C/en not_active Expired - Fee Related
- 2006-10-30 ES ES06795019T patent/ES2383967T3/es active Active
- 2006-10-30 RS RS20120235A patent/RS52312B/sr unknown
- 2006-10-30 RU RU2008121716/15A patent/RU2429845C2/ru not_active IP Right Cessation
- 2006-10-30 AT AT06795019T patent/ATE549023T1/de active
- 2006-10-30 NZ NZ567291A patent/NZ567291A/en not_active IP Right Cessation
- 2006-10-30 SI SI200631346T patent/SI1968592T1/sl unknown
- 2006-10-30 HR HRP20120478TT patent/HRP20120478T1/hr unknown
2008
- 2008-04-10 IL IL190774A patent/IL190774A/en not_active IP Right Cessation
- 2008-04-17 ZA ZA200803420A patent/ZA200803420B/xx unknown
- 2008-05-30 NO NO20082425A patent/NO341057B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
UA97629C2 (ru)	2012-03-12
WO2007052076A2 (en)	2007-05-10
AU2006310260A1 (en)	2007-05-10
DK1968592T3 (da)	2012-07-02
SI1968592T1 (sl)	2012-10-30
EP1968592A2 (de)	2008-09-17
NO341057B1 (no)	2017-08-14
IL190774A0 (en)	2008-11-03
JP2009513618A (ja)	2009-04-02
US20090076016A1 (en)	2009-03-19
JP5197373B2 (ja)	2013-05-15
AU2006310260B2 (en)	2012-08-09
CA2625096A1 (en)	2007-05-10
RU2429845C2 (ru)	2011-09-27
CN101300011A (zh)	2008-11-05
RS52312B (sr)	2012-12-31
KR20080064959A (ko)	2008-07-10
ES2383967T3 (es)	2012-06-27
NO20082425L (no)	2008-07-25
NZ567291A (en)	2011-04-29
HK1122743A1 (en)	2009-07-17
HRP20120478T1 (hr)	2012-07-31
AU2006310260C1 (en)	2013-09-19
CA2625096C (en)	2015-11-24
KR101434230B1 (ko)	2014-08-26
RU2008121716A (ru)	2009-12-10
CN101300011B (zh)	2011-12-28
WO2007052076A3 (en)	2008-03-20
EP1968592B1 (de)	2012-03-14
US9192568B2 (en)	2015-11-24
PT1968592E (pt)	2012-06-18
PL1968592T3 (pl)	2012-08-31
IL190774A (en)	2013-11-28
GB0522082D0 (en)	2005-12-07
ZA200803420B (en)	2009-10-28

Publication	Publication Date	Title
TW200621256A (en)	2006-07-01	Formulations
NO20082425L (no)	2008-07-25	Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer
ATE547102T1 (de)	2012-03-15	Carbolin-derivate zur behandlung von krebs
EA201790995A1 (ru)	2017-10-31	ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
ECSP088440A (es)	2008-06-30	Imidazopirazinas como inhibidores de proteinquinasa
NO20083002L (no)	2008-08-14	Fremgangsmate for anvendelse av CD40-bindende forbindelser
DE602006018057D1 (de)	2010-12-16	Substituierte chinolone und verwendungsverfahren
MX2009000285A (es)	2009-06-08	Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
DE602005012276D1 (de)	2009-02-26	Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
MX2009009761A (es)	2009-11-26	Composiciones y estuches para tratamiento de la influenza.
DE502004002571D1 (de)	2007-02-15	Substituierte 3-pyrrolidin-indol-derivate
ATE527241T1 (de)	2011-10-15	Pyridiazinonderivate zur behandlung von tumoren
DE602006007481D1 (de)	2009-08-06	5-amino-4-hydroxy-7-(imidazo ä1,2-aü pyridin-6-ylmethyl)-8-methylnonamidderivate und verwandte verbindungen als renininhibitoren zur behandlung von bluthochdruck
MX2008015775A (es)	2009-04-17	Compuestos y composiciones para tratamiento de cancer.
NO20064894L (no)	2007-01-03	Beta-karboliner anvendbare for behandling av inflammatoriske sykdommer
EA201070193A1 (ru)	2010-06-30	Лечение детских опухолей
DE602005015697D1 (de)	2009-09-10	Te zur behandlung von alzheimer-krankheit
ATE433459T1 (de)	2009-06-15	Desoxo-nonadepsipeptide
ATE475408T1 (de)	2010-08-15	Formulierungen von tipifarnib zur intravenösen verabreichung
ATE460168T1 (de)	2010-03-15	Nicht-radioaktives strontiummittel zur behandlung von krebs
DE602006013009D1 (de)	2010-04-29	Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs
DE602005015329D1 (de)	2009-08-20	Rutheniumkomplexe zur krebsbehandlung
EA200702136A1 (ru)	2008-04-28	Композиции станнсопорфина и их применение
DE60334289D1 (de)	2010-11-04	Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE481392T1 (de)	2010-10-15	Benzimidazolderivate zur behandlung entzündlicher erkrankungen